Tirzepatide Wholesale
Research-Grade Bulk Supply
The dual GIP/GLP-1 receptor agonist dominating metabolic research in 2026. HPLC-verified ≥98% purity, full COA every batch, 5mg to 30mg lyophilized vials — built for compounding pharmacies, clinics, and research institutions that need documentation they can rely on.
What Is Tirzepatide? The Dual GIP/GLP-1 Agonist Explained
Tirzepatide (LY3298176) is a synthetic 39-amino-acid peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It is the active ingredient in Eli Lilly’s Mounjaro® and Zepbound®, and the single most searched research peptide globally in 2026 with over one million monthly search queries for tirzepatide wholesale and related terms.
Unlike semaglutide — a selective GLP-1 agonist — tirzepatide activates two distinct incretin receptor pathways simultaneously. Research has established that tirzepatide demonstrates imbalanced receptor engagement, favoring the GIP receptor while exhibiting biased cAMP signaling at the GLP-1 receptor with reduced receptor internalization. This unique pharmacological fingerprint has made it the subject of intense metabolic research interest worldwide.
For wholesale buyers, tirzepatide is supplied as a research-grade lyophilized powder in hermetically sealed vials. HPLC-verified at ≥98% purity, every batch ships with a complete Certificate of Analysis including mass spectrometry identity confirmation, endotoxin testing, and residual solvent panel.
Dual Receptor Mechanism
Tirzepatide binds the GIP receptor with affinity equivalent to native GIP, while engaging the GLP-1 receptor with approximately 5× weaker affinity but with biased cAMP signaling. This imbalanced dual agonism produces a distinct pharmacological profile not achievable by either receptor alone.
Molecular Architecture
A 39-amino-acid sequence incorporating two non-coded aminoisobutyric acid (Aib) residues, an amidated C-terminus, and a C20 fatty diacid side chain attached via a PEG linker to lysine at position 20. This architecture extends half-life and enables subcutaneous delivery.
Research Demand — 2026
With 1,000,000+ monthly searches, tirzepatide is the #1 research peptide by search volume in 2026 — ahead of semaglutide (650K/mo) and retatrutide (250K/mo). Demand from compounding pharmacies and research institutions continues to outpace supply at many vendors.
Synthesis Complexity
Tirzepatide’s Aib substitutions, fatty acid conjugation, and PEG linker chemistry make synthesis technically demanding. This is why purity verification, a verifiable COA from an accredited third-party lab, and cold-chain handling are non-negotiable for serious research applications.
Tirzepatide Wholesale — Full Specifications
Every tirzepatide vial meets or exceeds the following specifications. COA documentation is available for every lot number prior to purchase.
Chemical & Molecular Data
| Peptide Name | Tirzepatide (LY3298176) |
| Sequence Length | 39 amino acids |
| Molecular Weight | 4,813.48 Da |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| CAS Number | 2023788-19-2 |
| Target Receptors | GIPR (primary), GLP-1R (biased) |
| Physical Form | Lyophilized powder |
| Solubility | Bacteriostatic water, sterile water |
Quality & Purity Standards
| HPLC Purity | ≥98% (batch tested) |
| Identity | Mass spectrometry confirmed |
| Endotoxin | <1 EU/mg (LAL method) |
| Sterility | Sterile-filtered, aseptic fill |
| Water Content | <5% (Karl Fischer) |
| Residual Solvents | ICH Q3C compliant |
| Storage (lyophilized) | -20°C · up to 24 months |
| Post-reconstitution | 4°C · use within 28 days |
Tirzepatide Wholesale Price — All Sizes 2026
Pricing is structured to reward volume. The larger the vial, the lower your cost per milligram. All prices include full COA documentation. Additional volume discounts at 25+ and 50+ unit orders.
| Size | Price Per Vial | Cost Per mg | Min. Order | 10+ Unit Price | Availability |
|---|---|---|---|---|---|
| Tirzepatide 5mg | $93 | $18.60 / mg | 5 vials | $81 / vial | ✓ In Stock |
| Tirzepatide 10mgBEST VALUE | $160 | $16.00 / mg | 5 vials | $142 / vial | ✓ In Stock |
| Tirzepatide 20mg | $285 | $14.25 / mg | 5 vials | $255 / vial | ✓ In Stock |
| Tirzepatide 30mg | $390 | $13.00 / mg | 5 vials | $350 / vial | ✓ In Stock |
How Tirzepatide Works — Dual Agonism Explained
Tirzepatide’s unique pharmacology stems from its ability to simultaneously engage two incretin hormone receptors with distinct signaling characteristics at each. Understanding this mechanism is essential for research protocol design and for differentiating tirzepatide from GLP-1–only compounds like semaglutide.
GIP Receptor Agonism
At the GIP receptor (GIPR), tirzepatide binds with affinity equivalent to native GIP, fully mimicking its action. GIP is the dominant incretin hormone in metabolically healthy individuals, responsible for the majority of post-prandial insulin secretion. Strong GIPR engagement is the primary differentiator from GLP-1–only agents.
Biased GLP-1R Signaling
At the GLP-1 receptor, tirzepatide acts as a biased agonist — preferentially driving cAMP generation over β-arrestin recruitment. This reduces receptor internalization compared to native GLP-1 or semaglutide, prolonging receptor surface expression and potentially enhancing downstream signaling duration.
Imbalanced Dual Engagement
Receptor occupancy modeling reveals tirzepatide engages the GIPR to a greater degree than the GLP-1R at studied doses. Research suggests this GIPR-dominant profile, combined with biased GLP-1R signaling, accounts for tirzepatide’s distinct efficacy profile relative to GLP-1–only agents.
Extrapancreatic Activity
Beyond pancreatic β cells, research has identified tirzepatide activity in adipose tissue (via GIPR), the central nervous system (anorexigenic GLP-1R signaling), and cardiovascular tissue — active areas of study for metabolic, neurological, and cardiometabolic research programs.
Tirzepatide in Peer-Reviewed Research — Key Study Areas
Tirzepatide is among the most actively studied peptide compounds in preclinical and clinical research in 2026. References below pertain to published scientific studies, not clinical claims.
Metabolic & Glycemic Research — SURPASS Trial Series
The SURPASS clinical program evaluated tirzepatide across multiple cohorts with type 2 diabetes. Published findings across SURPASS-1 through SURPASS-5 established tirzepatide’s HbA1c and body weight effects relative to comparator agents including semaglutide 1mg and insulin degludec, with dose-dependent outcomes at 5mg, 10mg, and 15mg weekly doses.
Published in NEJM, Lancet Diabetes & Endocrinology, 2021–2023
Body Composition Research — SURMOUNT Program
SURMOUNT-1 is the landmark body weight research publication for tirzepatide in non-diabetic populations. SURMOUNT-4 examined maintenance effects following dose titration. These studies established tirzepatide as one of the most efficacious weight-related compounds in the peer-reviewed literature with a published Phase 3 trial dataset.
Published in NEJM, JAMA, 2022–2023
Cardiovascular & Cardiometabolic Research
Tirzepatide is under active study for cardiometabolic outcomes including lipid profiles, blood pressure, and cardiovascular event reduction. The SURMOUNT-MMO cardiovascular outcomes trial is ongoing as of 2026, making tirzepatide a significant compound for cardiovascular metabolic research protocols.
Active trials registered at ClinicalTrials.gov
Neurological & Hepatic Research Frontiers
Emerging preclinical and early clinical data published through 2025 has explored tirzepatide in metabolic-associated fatty liver disease (MAFLD/NASH), Alzheimer’s disease neuroinflammation models, and Parkinson’s disease preclinical models — active research frontiers for 2026 wholesale buyers.
Publications in J. Hepatology, International Journal of Endocrinology, 2024–2025
What Separates Research-Grade Tirzepatide Wholesale
Tirzepatide synthesis is technically complex. Its Aib substitutions, fatty acid conjugation, and PEG linker chemistry create numerous opportunities for impurities and sequence errors that basic HPLC alone cannot detect. The documentation package must go beyond what most wholesale suppliers provide.
Full COA Per Lot
Every batch ships with a COA. Lot numbers match vials. Available pre-purchase on request.
HPLC + Mass Spec
Purity ≥98% by HPLC. Molecular weight confirmed by mass spectrometry — not just claimed.
Endotoxin Tested
LAL endotoxin testing <1 EU/mg. Sterility confirmed by aseptic fill and sterile filtration.
Cold-Chain Shipping
Lyophilized vials ship cold-chain. Stable at -20°C up to 24 months.
Sequence Verified
Amino acid sequence integrity verified. Aib residues and fatty acid conjugation confirmed per lot.
48h Fulfillment
In-stock orders ship within 48 business hours with tracking and cold-chain manifest.
Tirzepatide vs Semaglutide Wholesale — Key Differences
Both tirzepatide and semaglutide are widely purchased wholesale by compounding pharmacies and research institutions, but they are pharmacologically distinct compounds with different receptor profiles, molecular architectures, and research applications.
Semaglutide is a GLP-1 receptor agonist only. It binds the GLP-1R with high affinity and drives insulin secretion, gastric emptying reduction, and anorexigenic signaling through a single receptor pathway. It is a 31-amino-acid peptide modified with a C18 fatty acid for extended half-life.
Tirzepatide activates both the GIP receptor and the GLP-1 receptor simultaneously. Its imbalanced dual engagement — GIPR-dominant — and biased GLP-1R cAMP signaling produce a pharmacological profile that cannot be replicated by semaglutide. Tirzepatide is also structurally more complex, incorporating Aib residues and a C20 fatty diacid side chain, making synthesis more demanding and quality verification more critical. Per-mg pricing reflects this complexity.
The choice between the two compounds should be driven by research protocol requirements and receptor target — not pricing alone.
Who Buys Tirzepatide Wholesale
Tirzepatide wholesale supply is purpose-built for professional, licensed, and institutional buyers. Not available to the general public.
Compounding Pharmacies
503A and 503B pharmacies requiring documented tirzepatide API supply with full regulatory traceability.
Research Institutions
Universities, CROs, and biotech labs running preclinical metabolic, cardiovascular, or neurological research protocols.
Licensed Clinics
Weight management and metabolic health clinics operating under physician oversight with valid research procurement authorization.
Pharmaceutical CDMOs
Contract development and manufacturing organizations requiring research-grade tirzepatide for formulation development.
Peptide Distributors
B2B wholesale distributors supplying downstream licensed research buyers requiring volume pricing and documentation.
Longevity & Medical Practices
Anti-aging practices, regenerative medicine clinics, and longevity-focused medical groups with licensed research access.
Tirzepatide Wholesale — Frequently Asked Questions
Research Use Only: All products listed on this page, including tirzepatide, are sold strictly for in vitro research, laboratory, and compounding use only. These products are not intended for human or veterinary use, consumption, injection, or any therapeutic application. They are not FDA-approved drugs or dietary supplements. No claims are made regarding safety, efficacy, or therapeutic benefit in humans or animals. Buyers are solely responsible for compliance with all applicable federal, state, and local laws governing purchase, possession, and use of research chemicals and peptides. By purchasing, you confirm you are a licensed researcher, compounding pharmacist, or qualified institutional buyer acting within the scope of a legitimate research or compounding program.
Reviews
There are no reviews yet.